Bionomics announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder. Dr Papapetropoulos added, “We remain committed to advancing BNC210, a potential first- and best-in-class candidate with FDA Fast Track designation for both SAD and PTSD and look forward to sharing an update about our PTSD program following the recently completed EoPh2 meeting with the FDA.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNOX:
- Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
- Bionomics files to sell 3.64B ordinary shares for holders
- Bionomics Secures Growth Through Strategic Sale
- Bionomics Limited Announces Private Placement of up to $70.0 Million
- Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting